CHAMPIONS ONCOLOGY, INC. Deferred Revenue, Revenue Recognized
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Deferred Revenue, Revenue Recognized of $0 for the 12-month period ending 2017-04-30, per its 10-K filed 2017-07-28.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2017-07-28
- CHAMPIONS ONCOLOGY, INC. deferred revenue, revenue recognized for the quarter ending 2016-07-31 was $42.00K, a 75.00% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. deferred revenue, revenue recognized for the quarter ending 2015-07-31 was $24.00K.
- CHAMPIONS ONCOLOGY, INC. deferred revenue, revenue recognized for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- CHAMPIONS ONCOLOGY, INC. deferred revenue, revenue recognized for fiscal 2016 was $40.00K, a 94.48% decline from fiscal 2015.
- CHAMPIONS ONCOLOGY, INC. deferred revenue, revenue recognized for fiscal 2015 was $724.00K.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2017-04-30 | $0.00 10-K · filed 2017-07-28 | |||
| 2017-01-31 | $42.00K 10-Q · filed 2017-03-17 | |||
| 2016-10-31 | $42.00K 10-Q · filed 2016-12-14 | |||
| 2016-07-31 | $42.00K 10-Q · filed 2016-09-14 | |||
| 2016-04-30 | $40.00K 10-K · filed 2017-07-28 | |||
| 2016-01-31 | $48.00K 10-Q · filed 2017-03-17 | |||
| 2015-10-31 | $40.00K 10-Q · filed 2016-12-14 | |||
| 2015-07-31 | $24.00K 10-Q · filed 2016-09-14 | |||
| 2015-04-30 | $724.00K 10-K · filed 2016-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |